Oslo, Norway, February 12, 2026 - Lytix Biopharma AS ("Lytix" or the "Company")
today published its interim financial report for the second half of 2025 and
released its fourth quarter 2025 presentation.

The interim report has been prepared in accordance with IAS 34 and includes
financial information for the fourth quarter and the second half of 2025.

Q4 2025 highlights and developments
o	Positive interim clinical data from the Phase II NeoLIPA neoadjuvant melanoma
study were presented by Dr Henrik Jespersen at the Nordic Melanoma Meeting in
November 2025. Overall pathological responses was obtained in nearly 90% of
patients treated with ruxotemitide in combination with pembrolizumab.
o	Licensing partner Verrica Pharmaceuticals presented new immune-response data
from its ongoing Phase II study with ruxotemitide in basal cell carcinoma at the
Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting. 
o	The ATLAS-IT-05 Phase II study in advanced melanoma was completed, with
preparation of the clinical study report ongoing and expected to be finalized in
the first quarter of 2026.
o	Evaluating all strategic opportunities to accelerate the development of
LTX-401.
o	Cash and short-term financial investments totaled NOK 72.4 million at year-end
2025, reflecting disciplined cost management and reduced operating loss
following completion of major clinical activities.


Ruxotemitide is progressing toward commercialization via multiple avenues: our
internal work on neoadjuvant melanoma via the NeoLIPA study and our internal
planning towards a pivotal study